1208319-26-9

Product Details:

CasNo： 1208319-26-9

Molecular Formula： C15H23N5O2S

Purity： 99%

Synonyms: PF-03394197(oclacitinib); Oclacitinib PF-03394197; JAKi; trans-N-Methyl-4-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-cyclohexanemethanesulfonamide; CyclohexaneMethanesulfonaMide,N-Methyl-4-(Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMino)-,trans-; N-methyl-1-((1r,4r)-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide; N-Methyl-1-(trans-4-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclohexyl)methanesulfonamide
Melting point: 226-228°C
Density: 1.316±0.06 g/cm3
Solubility: DMSO (Slightly), Methanol (Slightly, Sonicated)
Pka: 11.59±0.40
Color: Off-White to Pale Beige
Form: Solid
Storage temp.: Refrigerator, Under inert atmosphere

Description:
Oclacitinib is an oral JAK inhibitor that is a drug approved by the U.S. Food and Drug Administration (FDA) for use in canine atopic dermatitis (AD). The U.S. FDA and the European Medical Association have approved a number of JAK inhibitors, including baricitinib, ruxolitinib, federatinib, tofacitinib, upadacitinib, oclacitinib, but some of these drugs are still being studied. Oclacitinib mainly shows activity against JAK1-dependent cytokines and also inhibits the function of JAK2-dependent cytokines. Oclacitinib modifies the production of cytokines such as IL-4 and IL-13, which are crucial for B-cell proliferation and maturation in the pathogenesis of pemphigus foliaceus. Oclacitinib could interdict the effects of IL-6, a cytokine involved in the Toll-like receptor 4-originated signaling pathway in the bladder epithelial cells, and IL-8, which could theoretically contribute to a decreased defense against the urinary pathogens.

Uses:
Oclacitinib is a novel Janus kinase (JAK) inhibitor with activity against cytokines involved in allergy.

Biological Activity:
janus kinase (jak) enzymes are involved in cell signaling pathways activated by cytokines dysregulated in allergy. Oclacitinib is a novel janus kinase inhibitor.